NO20055934L - Funksjonelt rekonstituerte virale virusmembraner - Google Patents

Funksjonelt rekonstituerte virale virusmembraner

Info

Publication number
NO20055934L
NO20055934L NO20055934A NO20055934A NO20055934L NO 20055934 L NO20055934 L NO 20055934L NO 20055934 A NO20055934 A NO 20055934A NO 20055934 A NO20055934 A NO 20055934A NO 20055934 L NO20055934 L NO 20055934L
Authority
NO
Norway
Prior art keywords
membranes
reconstituted viral
viral virus
functionally reconstituted
viral
Prior art date
Application number
NO20055934A
Other languages
English (en)
Inventor
Antonius Johannes Hen Stegmann
Jan Christiaan Wilschut
Johannes Henricus Garar Berkum
Original Assignee
Bestewil Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bestewil Holding Bv filed Critical Bestewil Holding Bv
Publication of NO20055934L publication Critical patent/NO20055934L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sammendrag Det beskrives vaksiner rettet mot antigener så som membranproteiner fra patogener eller tumorceller. Oppfinnelsen vedrører videre framgangsmåter for å danne · rekonstituerte virale membraner, med membranfusjonsaktivitet, som er lipidbisjiktmembraner fortrinnsvis inneholdende naturlige lipider av et virus, et viralt fusjonsprotein, en eller flere valgfritt ytterligere antigen og likeledes amfifile adjuvanser. Farmasøytiske materialer omfattende slike rekonstituerte virale membraner er også en del av oppfinnelsen.
NO20055934A 2003-06-19 2005-12-14 Funksjonelt rekonstituerte virale virusmembraner NO20055934L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300450 2003-06-19
PCT/NL2004/000437 WO2004110486A1 (en) 2003-06-19 2004-06-18 Functionally reconstituted viral membranes containing adjuvant

Publications (1)

Publication Number Publication Date
NO20055934L true NO20055934L (no) 2006-03-20

Family

ID=33550371

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055934A NO20055934L (no) 2003-06-19 2005-12-14 Funksjonelt rekonstituerte virale virusmembraner

Country Status (20)

Country Link
US (1) US7618641B2 (no)
EP (2) EP2368576B1 (no)
JP (1) JP4685005B2 (no)
KR (1) KR101225199B1 (no)
CN (1) CN100556454C (no)
AR (1) AR056245A1 (no)
AU (1) AU2004246974B2 (no)
BR (1) BRPI0411519A (no)
CA (1) CA2527735C (no)
DK (2) DK1633395T3 (no)
ES (2) ES2390454T3 (no)
IL (1) IL172584A (no)
MX (1) MXPA05013929A (no)
NO (1) NO20055934L (no)
PL (2) PL1633395T3 (no)
RU (1) RU2348428C2 (no)
TW (1) TWI329130B (no)
UA (1) UA87269C2 (no)
WO (1) WO2004110486A1 (no)
ZA (1) ZA200509907B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841860A2 (en) 2005-01-18 2007-10-10 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
AR059972A1 (es) * 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058002A1 (en) 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
AU2010210073B2 (en) 2009-02-06 2016-06-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Splitting gp41
CN102307592A (zh) 2009-02-06 2012-01-04 麦米提斯公司 新型gp41抗原
CN102905703B (zh) 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2622082A1 (en) * 2010-09-30 2013-08-07 Franvax S.r.l. Generation of virosome particles
US10806779B2 (en) 2013-07-02 2020-10-20 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
WO2016039620A2 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
RU2694367C2 (ru) * 2014-09-12 2019-07-12 Бестевил Холдинг Б.В. Способы получения адъювантных виросом и адъювантные виросомы, получаемые указанными способами
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3703734A1 (en) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
EP3847187A1 (en) 2018-09-03 2021-07-14 Laboratoire HRA-Pharma Zp3 fragments in immunotherapy of ovarian cancer
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
US20200188511A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2024088138A1 (zh) * 2022-10-25 2024-05-02 宁波明亦生物科技有限公司 质膜透化灭活口服疫苗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542212A (en) * 1975-10-14 1985-09-17 Institut Pasteur Phosphorylated 3-glyceryl-esters of glucose
JPS5929931B2 (ja) * 1980-12-09 1984-07-24 オムロン株式会社 安全スイツチ
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
JPH0688911B2 (ja) 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
DE69229703T2 (de) * 1991-05-08 2000-04-27 Schweiz Serum & Impfinst Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
DE69730218D1 (de) * 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen
EP1255561B1 (en) * 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteosome influenza vaccine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
WO2004045641A2 (en) * 2002-11-20 2004-06-03 Crucell Holland B.V. Antigen-complexes
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination

Also Published As

Publication number Publication date
AU2004246974A1 (en) 2004-12-23
ZA200509907B (en) 2006-11-29
EP1633395A1 (en) 2006-03-15
EP2368576A2 (en) 2011-09-28
US20060193873A1 (en) 2006-08-31
IL172584A (en) 2010-11-30
RU2006101394A (ru) 2006-06-10
JP2006527598A (ja) 2006-12-07
CN1805754A (zh) 2006-07-19
CA2527735A1 (en) 2004-12-23
BRPI0411519A (pt) 2006-08-01
MXPA05013929A (es) 2006-03-08
DK2368576T3 (en) 2015-05-18
PL2368576T3 (pl) 2015-12-31
CA2527735C (en) 2014-12-16
RU2348428C2 (ru) 2009-03-10
AU2004246974B2 (en) 2010-05-06
ES2536689T3 (es) 2015-05-27
DK1633395T3 (da) 2012-10-29
JP4685005B2 (ja) 2011-05-18
ES2390454T3 (es) 2012-11-13
EP2368576A3 (en) 2012-03-28
CN100556454C (zh) 2009-11-04
PL1633395T3 (pl) 2012-12-31
UA87269C2 (ru) 2009-07-10
EP1633395B1 (en) 2012-08-01
US7618641B2 (en) 2009-11-17
EP2368576B1 (en) 2015-02-25
WO2004110486A1 (en) 2004-12-23
IL172584A0 (en) 2006-04-10
KR101225199B1 (ko) 2013-01-23
KR20060030047A (ko) 2006-04-07
TWI329130B (en) 2010-08-21
AR056245A1 (es) 2007-10-03
TW200510538A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
NO20055934L (no) Funksjonelt rekonstituerte virale virusmembraner
JP7514206B2 (ja) コロナウイルスワクチン
Kuate et al. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies
US20230330215A1 (en) Sars-cov-2 vaccines
ES2811093T3 (es) Arenavirus trisegmentados como vectores de vacunas
JP2023526178A (ja) コロナウイルスワクチン
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
NO20050008L (no) Neisserial vaksinesammensetninger omfattende en kombinasjon av antigener
Mirzaei et al. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
NO20054608L (no) Influensavirusvaksine
NO20072253L (no) Forbedrede vaksiner
WO2012149045A3 (en) Liposomal formulations
US20220347291A1 (en) Vaccine for use in the prophylaxis and/or treatment of a disease
WO2007008070A3 (en) ADJUVATION THROUGH CROSS-β STRUCTURE
TW202333780A (zh) 冠狀病毒疫苗
CY1111549T1 (el) Συνθεσεις για ανοσοποιηση εναντι μυκοβακτηριδιου
Sharifzadeh et al. A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases
WO2006071896A3 (en) Epitope-based sars vaccine
Bohnen et al. Vaccination with recombinant modified vaccinia virus A nkara prevents the onset of intestinal allergy in mice
JP2017509713A (ja) アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法
CN116650633A (zh) 冠状病毒疫苗
TH72411A (th) เมมเบรนไวรัสที่ประกอบขึ้นใหม่เชิงหน้าที่ที่มีสารเสริม
RIFI et al. Membrane biophysical and structural investigations of HIV-1 envelope glycoproteins epitopes in the aim of eliciting liposomal vaccine
Liu et al. 561. Recombinant Adenovirus Carrying Spike Gene Induces Effective Humoral and Cellular Immunity Against SARS-CoV in Rats

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application